Previous 10 | Next 10 |
CAMBRIDGE, Mass., June 04, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today announced that Craig Wheeler, President and CEO, will pre...
CAMBRIDGE, Mass., May 09, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today announced that Craig Wheeler, President and CEO, will pres...
Shares of Momenta Pharmaceuticals ( MNTA ) have risen by just 28% over the past five years and lost a third of their value over the past twelve months. Year to date in 2019 the stock has posted a 30% gain as a recovery looks to be in the works. Formerly known primarily as a play on the com...
Biogen ( BIIB ) - The company announced interim results from a phase 1/2 study of tofersen (antisense oligonucleotide) being studied for the treatment of amyotrophic lateral sclerosis ((ALS)). Data was sufficiently encouraging to support initiation of phase 3 study in SOD1-ALS patients and ...
Momenta Pharmaceuticals, Inc. (MNTA) Q1 2019 Earnings Conference Call May 02, 2019, 08:30 ET Company Participants Patricia Eisenhaur - VP, IR & Communications Craig Wheeler - President, CEO & Executive Director Michelle Robertson - Principal Accounting Officer, CFO, Treas...
The following slide deck was published by Momenta Pharmaceuticals, Inc. in conjunction with their 2019 Q1 earnings Read more ...
Momenta Pharmaceuticals (NASDAQ: MNTA ): Q1 GAAP EPS of -$0.46 misses by $0.04 . More news on: Momenta Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
— M281 Phase 2 trials in MG and HDFN active and enrolling patients — — Data supporting M281’s mechanism in HDFN, as first anti-FcRn antibody to inhibit maternal-fetal IgG transfer in perfusion model of the human term placenta, published in American Journal ...
CAMBRIDGE, Mass., April 18, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today announced that it will release its financial results for...
AbbVie ( ABBV ) was able to obtain its first approval for SKYRIZI (risankizumab) in Japan for treating patients with psoriasis. This is good news, but the market opportunity in Japan is not better than that of the United States or Europe. It won't be long for potential U.S. approval at all...
News, Short Squeeze, Breakout and More Instantly...
Momenta Pharmaceuticals Inc. Company Name:
MNTA Stock Symbol:
NASDAQ Market:
Momenta Pharmaceuticals Inc. Website:
Are These Top 3 Pharmaceutical Stocks On Your October Watchlist? Investing in pharmaceutical stocks is a popular trend in times of political or economic instability. This is because the demand for drugs will still be steady all year long, no matter what is happening in the world...
Chesapeake Utilities to Join S&P SmallCap 600 Chesapeake Utilities to Join S&P SmallCap 600 PR Newswire NEW YORK, Sept. 25, 2020 NEW YORK , Sept. 25, 2020 /PRNewswire/ -- Chesapeake Utilities Corp (NYSE:CPK) will replace Momenta Pharmaceuticals In...
NEW YORK, NY / ACCESSWIRE / September 23, 2020 / Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York City, is investigating: Akcea Therapeutics, Inc. (NASDAQ: AKCA ), relating...